sulindac and Leukemia--Myeloid

sulindac has been researched along with Leukemia--Myeloid* in 1 studies

Other Studies

1 other study(ies) available for sulindac and Leukemia--Myeloid

Article	Year
Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS. British journal of haematology, 2006, Volume: 135, Issue:3 The influence of Exisulind on the viability and apoptosis of CD34(+) stem cells from patients with advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML)/MDS was investigated. In eight out of 10 patient samples Exisulind reduced the fraction of viable cells by inducing apoptosis. We found evidence that Exisulind-mediated apoptosis depends on c-Jun NH(2)-terminal kinase (JNK) activation. Addition of a specific JNK-inhibitor to Exisulind-treated advanced MDS and AML/MDS cells partly abrogated apoptosis. We propose that Exisulind is tested in clinical phase I/II trials for the treatment of advanced MDS and AML/MDS. Topics: Acute Disease; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Survival; Cells, Cultured; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid; Myelodysplastic Syndromes; Stem Cells; Sulindac	2006

Article

Year

Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS.

British journal of haematology, 2006, Volume: 135, Issue:3

The influence of Exisulind on the viability and apoptosis of CD34(+) stem cells from patients with advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML)/MDS was investigated. In eight out of 10 patient samples Exisulind reduced the fraction of viable cells by inducing apoptosis. We found evidence that Exisulind-mediated apoptosis depends on c-Jun NH(2)-terminal kinase (JNK) activation. Addition of a specific JNK-inhibitor to Exisulind-treated advanced MDS and AML/MDS cells partly abrogated apoptosis. We propose that Exisulind is tested in clinical phase I/II trials for the treatment of advanced MDS and AML/MDS.

Topics: Acute Disease; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Survival; Cells, Cultured; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid; Myelodysplastic Syndromes; Stem Cells; Sulindac

2006